Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Connell

Showing results (311-320 of 350) with videos related to

Pageof 35
Sort By:
The Journal of Hospital Infection|October 14, 2014
Endoscopy supply water and final rinse testing: five years of experienceA Marek, A Smith, M Peat, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|June 21, 2024
Inflammatory Cells in Control and Prolapsed Uterosacral Ligament TissueDavid J Orlicky, E Erin Smith, Joshua Johnson, et al.
International Urogynecology Journal|July 7, 2026
Gut microbiome profile and inflammatory response in pelvic organ prolapse: A pilot studyAshley E Hilton, Dylan M Asmar, David J Orlicky, et al.
Journal of Clinical Medicine|June 7, 2020
Randomized Trial of General Strength and Conditioning Versus Motor Control and Manual Therapy for Chronic Low Back Pain on Physical and Self-Report OutcomesScott D Tagliaferri, Clint T Miller, Jon J Ford, et al.
Annals of the Rheumatic Diseases|August 3, 2022
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trialAndra-Rodica Balanescu, Gustavo Citera, Virginia Pascual-Ramos, et al.
Annals of the Rheumatic Diseases|March 14, 2013
Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised studyIain B McInnes, Ho-Youn Kim, Sang-Heon Lee, et al.
Arthritis and Rheumatism|September 29, 2011
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugsRoy Fleischmann, Maurizio Cutolo, Mark C Genovese, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 28, 2022
Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy IndividualsXiaoxing Wang, Martin E Dowty, Ann Wouters, et al.
Therapeutic Advances in Musculoskeletal Disease|November 9, 2023
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a <i>post hoc</i> analysis of ORAL SurveillanceGeorge A Karpouzas, Zoltán Szekanecz, Eva Baecklund, et al.
Annals of the Rheumatic Diseases|January 4, 2023
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trialJeffrey R Curtis, Kunihiro Yamaoka, Yi-Hsing Chen, et al.
Pageof 35

Showing results (311-320 of 350) with videos related to

Sort By:
Pageof 35
The Journal of Hospital Infection|October 14, 2014
Endoscopy supply water and final rinse testing: five years of experienceA Marek, A Smith, M Peat, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|June 21, 2024
Inflammatory Cells in Control and Prolapsed Uterosacral Ligament TissueDavid J Orlicky, E Erin Smith, Joshua Johnson, et al.
International Urogynecology Journal|July 7, 2026
Gut microbiome profile and inflammatory response in pelvic organ prolapse: A pilot studyAshley E Hilton, Dylan M Asmar, David J Orlicky, et al.
Journal of Clinical Medicine|June 7, 2020
Randomized Trial of General Strength and Conditioning Versus Motor Control and Manual Therapy for Chronic Low Back Pain on Physical and Self-Report OutcomesScott D Tagliaferri, Clint T Miller, Jon J Ford, et al.
Annals of the Rheumatic Diseases|August 3, 2022
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trialAndra-Rodica Balanescu, Gustavo Citera, Virginia Pascual-Ramos, et al.
Annals of the Rheumatic Diseases|March 14, 2013
Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised studyIain B McInnes, Ho-Youn Kim, Sang-Heon Lee, et al.
Arthritis and Rheumatism|September 29, 2011
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugsRoy Fleischmann, Maurizio Cutolo, Mark C Genovese, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 28, 2022
Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy IndividualsXiaoxing Wang, Martin E Dowty, Ann Wouters, et al.
Therapeutic Advances in Musculoskeletal Disease|November 9, 2023
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a <i>post hoc</i> analysis of ORAL SurveillanceGeorge A Karpouzas, Zoltán Szekanecz, Eva Baecklund, et al.
Annals of the Rheumatic Diseases|January 4, 2023
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trialJeffrey R Curtis, Kunihiro Yamaoka, Yi-Hsing Chen, et al.
Pageof 35